A preprint in 84 older adults with epilepsy found that abnormal Alzheimer's-related blood biomarkers were common, but the biomarker categories did not line up neatly with cognitive impairment. Research Highlights Only 32.1% had normal biomarkers: 27 of 84 older adults with epilepsy were A−T−N− using blood-based amyloid, tau, and neurodegeneration markers.1 AD-continuum profiles were common: …
A 91-player adolescent football preprint mapped head-impact-related cortical slowing onto brain receptor and gene-expression maps: concussion-related slowing aligned with norepinephrine transporter density, r = 0.43, and alpha-4 beta-2 nicotinic receptor density, r = 0.50, while aligning inversely with dopamine D2, BDNF, and APOE maps.1 The result is a mechanistic clue about where head-impact physiology may …
A 2026 Molecular Psychiatry study found that RVI-AD, a structural-MRI score measuring how closely a person’s brain anatomy matches an Alzheimer’s disease pattern, predicted mild-cognitive-impairment conversion to dementia most strongly over the next 3 years: OR 2.16, 95% CI 1.81-2.57, p < 2e-16, AUC 0.70.1 Research Highlights Short-term conversion signal: in 965 ADNI participants with …
Until recently, Alzheimer’s pathology could only be confirmed in living patients via PET imaging or lumbar puncture. Plasma p-tau217 changed that calculus — but how to interpret a positive result depends substantially on APOE genotype.1 Research Highlights Plasma p-tau217 is a blood biomarker that rises years before Alzheimer’s symptoms. The 2024 Alzheimer’s Association revised criteria …